Collaborating for Impact in Implementing Canada’s National Strategy for Rare Disease Drugs

The federal government has committed $1.5 billion over three years to help provinces and territories cover the costs of high-priced rare disease treatments. Implementing the National Strategy for Drugs for Rare Diseases requires ongoing collaboration, transparency, and adaptability among all stakeholders. Walk away with an action plan on:

• Understanding the challenges still faced by patients across Canada on receiving access to the right treatments.
• Assessing the steps towards collaboration made in 2025 at the provincial, federal, and industry level.
• Exploring how this funding has reduced treatment delays, improved patient outcomes, and fostered a more sustainable rare disease drug ecosystem.

Improve coordination of access to treatments for rare disease patients to ensure timely, equitable access to life-saving therapies and enhance overall patient outcomes.